Defensins are dominant HLA-DR-associated self-peptides from CD34- peripheral blood mononuclear cells of different tumor patients (plasmacytoma, chronic myeloid leukemia)

Blood

Volumn 95, Issue 9, 2000, Pages 2890-2896

  Halder, Thomas M ^b   Blüggel, Martin ^b   Heinzel, Susanne ^b   Pawelec, Graham ^b   Meyer, Helmut E ^b   Kalbacher, Hubert ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CD34 ANTIGEN; DEFENSIN; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; CARCINOGENESIS; CASE REPORT; CELL PROLIFERATION; CELL STIMULATION; CHRONIC MYELOID LEUKEMIA; GEL PERMEATION CHROMATOGRAPHY; HUMAN; LEUKAPHERESIS; MONONUCLEAR CELL; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN ISOLATION; T LYMPHOCYTE;

EID: 0343618527     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.9.2890.009k09_2890_2896     Document Type: Article

References (38)

1. Accolla RS, Scupoli MT, Cambiaggi C, Tosi G, Sartoris S. Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression. Int J Cancer Suppl. 1991;6:20.
2. Silacci P, Mottet A, Steimle V, Reith W, Mach B. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J Exp Med. 1994;180:1329.
3. Harris PE, Maffei A, Colovai AI, Kinne J, Tugulea S, Suciu-Foca N. Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins. Blood 1996;87:5104.
4. Papadopoulos KP, Suciu-Foca N, Hesdorffer CS, Tugulea S, Maffei A, Harris PE. Naturally processed tissue-and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood. 1997;90:4938.
5. Lehrer RI, Lichtenstein AK, Ganz T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol. 1993;11:105.
6. Ganz T, Lehrer RI. Defensins. Curr Op Immunol. 1994;6:584.
7. Hancock REW. Peptide antibiotics. Lancet. 1997; 349:418.
8. Hill CP, Yee J, Selsted ME, Eisenberg D. Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science. 1991;251:1481.
9. White SH, Wimley WC, Selsted ME. Structure, function, and membrane integration of defensins. Curr Opin Struct Biol. 1995;5:521.
10. Okrent DG, Lichtenstein AK, Ganz T. Direct cytotoxicity of polymorphonuclear leukocyte granule proteins to human lung-derived cells and endothelial cells. Am J Respir Cell Mol Biol. 1991;5: 101.
11. Yamashita T, Saito K. Purification, primary structure, and biological activity of guinea pig neutrophil cationic peptides. Infect Immun. 1989;57:2405.
12. Territo MC, Ganz T, Selsted ME, Lehrer RI. Monocyte chemotactic activity of defensins from human neutrophils. J Clin Invest. 1989;84:2017.
13. Chertov O, Michiel DF, Xu L, et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem. 1997;271:2935.
14. Prohaszka Z, Nemet K, Csermely P, Hudecz F, Mezo G, Füst G. Defensins purified from human granulocytes bind C1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 of HIV-1. Mol Immunol. 1997; 34:809.
15. Van den Berg RH, Faber-Krol MC, von Wetering S, Hiemstra PS, Daha MR. Inhibition of activation of the classical pathway of complement by human neutrophil defensins. Blood. 1998;92:3898.
16. Higazi AAR, Lavi E, Bdeir K, et al. Defensins stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood. 1997;89:4290.
17. Lillard JW, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci U S A. 1999;96:651.
18. Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kalbacher H. Isolation of novel HLA-DR-restricted potential tumor antigens from the melanoma cell line FM3. Cancer Res. 1997;57:3238.
19. Bateman A, Singh A, Shustik C, Mars WM, Solomon S. The isolation and identification of multiple forms of the neutrophil granule peptides from human leukemic cells. J Biol Chem. 1991;266:7524.
20. Max H, Halder T, Kaibus M, Gnau V, Jung G, Kalbacher H. A 16mer peptide of the human autoantigen calreticulin is a most prominent HLA-DR4Dw4-associated self-peptide. Hum Immunol. 1994;41:39.
21. rd-party co-stimulation for human T-cell activation. Immunology 1993;80:242.
22. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 1993;178:27.
23. Busch R, Strang G, Howland K, Rothbard JB. Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int Immunol. 1990;2:443.
24. Sette A, Southwood S, Miller J, Appella E. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med. 1995;181:677.
25. Gosselin EJ, Wardwell, K, Rigby WF, Guyre PM. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3. J Immunol. 1993;151:1482.
26. Mudzinski SP, Christian TP, Guo E, Cirenza E, Hazlett KR, Gosselin EJ. Expression of HLA-DR (major histocompatibility complex class II) on neutrophils from patients treated with granulocyte-macrophage colony-stimulating factor for mobilization of stem cells [letter]. Blood 1995;86: 2452.
27. Smith WB, Guida L, Sun Q, et al. Neutrophils activated by granulocyte-macrophage colony-stimulating factor express receptors for interleukin-3 which mediate class II expression. Blood. 1995; 86:3938.
28. Reinisch W, Tillinger W, Lichtenberger C, et al. In vivo induction of HLA-DR on human neutrophils in patients treated with interferon-γ [letter]. Blood. 1996;87:3068.
29. Fanger NA, Liu C, Guyre PM, et al. Activation of human T cells by major histocompatibility complex class II expressing neutrophils: proliferation in the presence of superantigen, but not tetanus toxoid. Blood. 1997;89:4128.
30. Brown JH, Jardetzky TS, Gorga JC, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 1993; 364:33.
31. Kropshofer H, Vogt AB, Stern LJ, Hämmerling GJ. Self release of CLIP in peptide loading of HLA-DR molecules. Science. 1995;270:1357.
32. Cunningham AC, Zhang JG, Moy JV, Ali S, Kirby JA. A comparison of class II MHC-expressing human lung epithelial and endothelial cells. Immunology 1997;91:458.
33. Panja A, Barone A, Mayer L. Stimulation of lamina propria lymphocytes by intestinal epithelial cells: evidence for recognition of nonclassical restriction elements. J Exp Med. 1994;179:943.
34. Hoyne GF, Callow MG, Kuo MC, Thomas WR. Presentation of peptides and proteins by intestinal epithelial cells. Immunology. 1993;80:204.
35. Hershberg RM, Cho DH, Youakim A, et al. Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells. J Clin Invest. 1998;102:792.
36. Wilson JL, Cunningham AC, Kirby JA. Alloantigen presentation by B cells: analysis of the requirement for B-cell activation. Immunology. 1995;86: 325.
37. Leon MP, Bassendine MF, Wilson JL, Ali S, Thick M, Kirby JA. Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells. Hepatology. 1996;24:561.
38. Rammensee HG, Friede T, Slevanovic S. MHC ligands and peptide motif: first listing. Immunogenetics. 1995;41:178.